GLP1R and type 2 diabetes mellitus: Notably, the phase 2randomized LIXIPARK trial assessed lixisenatide—a GLP-1 receptor agonisttypically prescribed for type 2 diabetes—as a possible disease-modifyingintervention in early-stage PD.